[O2–14–05]: PRECLINICAL CHARACTERIZATION OF AN ANTIBODY [LY3303560] TARGETING AGGREGATED TAU-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

[O2–14–05]: PRECLINICAL CHARACTERIZATION OF AN ANTIBODY [LY3303560] TARGETING AGGREGATED TAU

Published:2017-07 Issue:7S_Part_11 Volume:13 Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Alam Riazul¹²,Driver David¹,Wu Su¹,Lozano Emmanuel¹,Key Stephanie L.¹,Hole Justin T.¹,Hayashi Mansuo L.¹,Lu Jirong¹

Affiliation:

1. Eli Lilly and CompanyIndianapolisINUSA

2. Eli Lilly and CompanySan DiegoCAUSA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2017.07.227

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Efficacy and Safety of Zagotenemab;Neurology;2024-03-12

2. Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials;Ageing Research Reviews;2023-12

3. Untangling Tau: Molecular Insights into Neuroinflammation, Pathophysiology, and Emerging Immunotherapies;Current Issues in Molecular Biology;2023-11-02

4. Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial;Journal of Alzheimer's Disease Reports;2023-09-15

5. Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks;Frontiers in Aging Neuroscience;2023-08-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP